Supriya Lifescience Limited (NSE:SUPRIYA)
644.45
+6.55 (1.03%)
Nov 12, 2026, 3:29 PM IST
Supriya Lifescience Revenue
Supriya Lifescience had revenue of 2.09B INR in the quarter ending September 30, 2026, with 4.38% growth. This brings the company's total for the last twelve months to 8.79B, up 22.93% year-over-year. In the fiscal year ending March 31, 2026, Supriya Lifescience had annual revenue of 8.28B with 18.86% growth. That makes Supriya Lifescience the 23,162nd largest company in the world by revenue and 1,409th in India.
Revenue (ttm)
8.79B
Revenue Growth
+22.93%
P/S Ratio
5.90
Revenue / Employee
14.47M
Employees
607
Market Cap
51.87B
Revenue by Geography
- Europe 3.31B 40.0%
- Asia 2.73B 33.0%
- Latin America 1.66B 20.0%
- Others 331.15M 4.0%
- North America 248.36M 3.0%
Fiscal year ended Mar 31, 2026 See the full Supriya Lifescience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.28B | 1.31B | 18.86% |
| Mar 31, 2025 | 6.96B | 1.26B | 22.12% |
| Mar 31, 2024 | 5.70B | 1.09B | 23.73% |
| Mar 31, 2023 | 4.61B | -691.11M | -13.04% |
| Mar 31, 2022 | 5.30B | 1.39B | 35.49% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 174.15B |
| Dishman Carbogen Amcis | 29.01B |
| Anthem Biosciences | 20.50B |
| OneSource Specialty Pharma | 16.86B |
| Concord Biotech | 11.70B |
| Blue Jet Healthcare | 11.05B |
| Zota Health Care | 6.79B |
| Panacea Biotec | 6.73B |